(Q48793686)

15 February 2018

title

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients (English)

1 reference

15 February 2018

1 reference

Diaz-Martinez A

1

1 reference

15 February 2018

Benassinni O

2

1 reference

15 February 2018

Ontiveros A

3

1 reference

15 February 2018

Gonzalez S

4

1 reference

15 February 2018

Salin R

5

1 reference

15 February 2018

Basquedano G

6

1 reference

15 February 2018

Martinez RA

7

1 reference

15 February 2018

publication date

1 May 1998

1 reference

15 February 2018

published in

Clinical Therapeutics

1 reference

15 February 2018

volume

20

1 reference

15 February 2018

issue

3

1 reference

15 February 2018

page(s)

467-476

1 reference

15 February 2018

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

Efficacy of venlafaxine in depressive illness in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

Pharmacotherapeutic profile of venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

1 reference

7 January 2021

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

Drug-drug interactions involving antidepressants: focus on venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980056-8

7 January 2021

10.1016/S0149-2918(98)80056-8

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018